Bosutinib

Borosil&reg Plastic Polypropylene Flat Head Stoppers are with Interchangeable Joint and can be used with Volumetric Flask of 5645, 5647 families or for other suitable joints. Polypropylene available in sizes of 7/16 to 34/35.

Borosil&reg Plastic Polypropylene Flat Head Stoppers are with Interchangeable Joint and can be used with Volumetric Flask of 5645, 5647 families or for other suitable joints. Polypropylene available in sizes of 7/16 to 34/35.

Borosil&reg Reagent Square Bottles are perfect for storing media, solvents, and other materials. Bottles comes with PP Screw cap (GL80).

Borosil&reg Reagent Square Bottles are perfect for storing media, solvents, and other materials. Bottles comes with PP Screw cap (GL80).

Please join us to support breast cancer prevention, treatment, and research by purchasing Pink Colorware from Kimble&reg. We will donate 20% of the proceeds to the Breast Cancer Research Foundation, the highest rated breast cancer organization in

Please join us to support breast cancer prevention, treatment, and research by purchasing Pink Colorware from Kimble&reg. We will donate 20% of the proceeds to the Breast Cancer Research Foundation, the highest rated breast cancer organization in

Other Notes Please note that Sigma-Aldrich provides this product to early discovery researchers as part of a collection of rare and unique chemicals. Sigma-Aldrich does not collect analytical data for this product.

Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effectively interfere with the progress of chronic myelogenous leukemia (CML). In a competitive study with Imatinib, Bosutinib was shown to inhibit Bcr-Abl kinase

Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effectively interfere with the progress of chronic myelogenous leukemia (CML). In a competitive study with Imatinib, Bosutinib was shown to inhibit Bcr-Abl kinase

Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effectively interfere with the progress of chronic myelogenous leukemia (CML). In a competitive study with Imatinib, Bosutinib was shown to inhibit Bcr-Abl kinase

Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effectively interfere with the progress of chronic myelogenous leukemia (CML). In a competitive study with Imatinib, Bosutinib was shown to inhibit Bcr-Abl kinase

Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effectively interfere with the progress of chronic myelogenous leukemia (CML). In a competitive study with Imatinib, Bosutinib was shown to inhibit Bcr-Abl kinase